%0 Journal Article %J Nat Commun %D 2019 %T Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. %A Menden, Michael P %A Wang, Dennis %A Mason, Mike J %A Szalai, Bence %A Bulusu, Krishna C %A Guan, Yuanfang %A Yu, Thomas %A Kang, Jaewoo %A Jeon, Minji %A Wolfinger, Russ %A Nguyen, Tin %A Zaslavskiy, Mikhail %A Jang, In Sock %A Ghazoui, Zara %A Ahsen, Mehmet Eren %A Vogel, Robert %A Neto, Elias Chaibub %A Norman, Thea %A Tang, Eric K Y %A Garnett, Mathew J %A Veroli, Giovanni Y Di %A Fawell, Stephen %A Stolovitzky, Gustavo %A Guinney, Justin %A Dry, Jonathan R %A Saez-Rodriguez, Julio %K ADAM17 Protein %K Antineoplastic Combined Chemotherapy Protocols %K Benchmarking %K Biomarkers, Tumor %K Cell Line, Tumor %K Computational Biology %K Datasets as Topic %K Drug Antagonism %K Drug Resistance, Neoplasm %K Drug Synergism %K Genomics %K Humans %K Molecular Targeted Therapy %K mutation %K Neoplasms %K pharmacogenetics %K Phosphatidylinositol 3-Kinases %K Phosphoinositide-3 Kinase Inhibitors %K Treatment Outcome %X

The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop resistance that might be overcome with drug combinations. However, the number of possible combinations is vast, necessitating data-driven approaches to find optimal patient-specific treatments. Here we report AstraZeneca's large drug combination dataset, consisting of 11,576 experiments from 910 combinations across 85 molecularly characterized cancer cell lines, and results of a DREAM Challenge to evaluate computational strategies for predicting synergistic drug pairs and biomarkers. 160 teams participated to provide a comprehensive methodological development and benchmarking. Winning methods incorporate prior knowledge of drug-target interactions. Synergy is predicted with an accuracy matching biological replicates for >60% of combinations. However, 20% of drug combinations are poorly predicted by all methods. Genomic rationale for synergy predictions are identified, including ADAM17 inhibitor antagonism when combined with PIK3CB/D inhibition contrasting to synergy when combined with other PI3K-pathway inhibitors in PIK3CA mutant cells.

%B Nat Commun %V 10 %P 2674 %8 2019 06 17 %G eng %N 1 %1 https://www.ncbi.nlm.nih.gov/pubmed/31209238?dopt=Abstract %R 10.1038/s41467-019-09799-2